LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for D-penicillamine (CUPROS L), CUPROS L belongs to the group of medicines called disease-modifying antirheumatic drugs (DMARDS).
Penicillamine works by reducing the body’s immune response and relieving the pain, swelling, and stiffness caused by rheumatoid arthritis.
Penicillamine is also a chelating agent which means it binds to certain metals in your body, including lead and copper, to help eliminate them from the human body.
CUPROS L is a medication primarily used for the treatment of Wilson’s disease. Also used for the tratment Rheumatoid arthritis, in cases of lead or other heavy metal poisoning and in cystinuria.
